Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - trabectedin 0,25 mg - powder for concentrate for solution for infusion - trabectedin

Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - trabectedin 1 mg - powder for concentrate for solution for infusion - trabectedin

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - trabectedin - powder for solution for infusion - 250microgram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - trabectedin - powder for solution for infusion - 1mg

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

pharma mar s.a. - trabectedin - ovarian neoplasms; sarcoma - antineoplastic agents - yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.yondelis in combination with pegylated liposomal doxorubicin (pld) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.

Kanada - Kiingereza - Health Canada

valeo pharma inc - trabectedin - powder for solution - 1mg - trabectedin 1mg - antineoplastic agents

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

specialised therapeutics pharma pty ltd - trabectedin, quantity: 1 mg - injection, powder for - excipient ingredients: monobasic potassium phosphate; sucrose; potassium hydroxide; phosphoric acid - yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

specialised therapeutics pharma pty ltd - trabectedin, quantity: 0.25 mg - injection, powder for - excipient ingredients: sucrose; monobasic potassium phosphate; potassium hydroxide; phosphoric acid - yondelis is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.

Singapoo - Kiingereza - HSA (Health Sciences Authority)

specialised therapeutics asia pte ltd - trabectedin - injection, powder, for solution - 1.0mg/vial - trabectedin 1.0mg/vial

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

pharma mar, s.a. - trabectedin - powder for solution for infusion - 250microgram